Tuesday, April 26, 2011 9:25:54 AM
In another matter CGAQ has received concerns from investors regarding discounted free trades that were sold to raise money for company expansion posted on the 3rd quarter financials; this is currently being revised and will be corrected in the yearend financial report.
On this matter Mr. Swank stated, "I'd like to thank the people who brought this to our attention, once I heard of this matter I got in touch with the company's CPA and we are having them revised as this is a horrible mistake. Selling discounted stock to keep the company debt free and yet continue to expand is something normal for public companies, but discounted at the prices that have been posted is just ridiculous."
These guys are still unloading shares at a 50%+ discount. Nothing has changed except dilution of another 50 million shares over the last few months. They continue to dilute shares at "ridiculous" discounts that Swank himself said was not the case.
The only correction I see on the sale of shares is the sale on 12/10. They previously listed the 8mill+ sold at .09 when in fact they were sold at almost half that! The only mistake was they reported a 46% discount when in actuality it was a 67% discount! These guys cant even keep their lies straight anymore.
Since January alone they have diluted 22.5 million shares sold at about .0055. The pps at the time was anywhere from 1-2 cents. Do the math.
Recent BSEM News
- BioStem Technologies Announces $2.5 Million Private Placement Financing with its First Institutional Investor • GlobeNewswire Inc. • 05/22/2026 11:00:00 AM
- BioStem Technologies Announces Notice of Allowance for Four U.S. Design Patent Applications Covering Fenestrated Human Placental Allografts and One European Patent • GlobeNewswire Inc. • 05/20/2026 01:00:00 PM
- BioStem Technologies Reports First Quarter 2026 Financial Results • GlobeNewswire Inc. • 05/14/2026 08:05:00 PM
- BioStem Technologies to Host First Quarter 2026 Financial Results Conference Call on May 14, 2026 • GlobeNewswire Inc. • 04/30/2026 08:05:00 PM
- BioStem Strengthens Leadership Team with Appointment of Katherine Gorrell as Chief Legal & Compliance Officer • GlobeNewswire Inc. • 04/30/2026 11:00:00 AM
- BioStem Technologies to Showcase Innovation and Clinical Evidence at Symposium on Advanced Wound Care Spring 2026 • GlobeNewswire Inc. • 04/08/2026 11:00:00 AM
- BioStem Technologies to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/31/2026 08:05:00 PM
- BioStem Technologies Announces the Publication of its Audited Financial Statements for Fiscal Years 2024 and 2025 • GlobeNewswire Inc. • 03/30/2026 11:00:00 AM
- BioStem Technologies Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 03/24/2026 08:05:00 PM
- BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair • GlobeNewswire Inc. • 03/23/2026 03:40:56 PM
- BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair • GlobeNewswire Inc. • 03/23/2026 11:00:00 AM
- BioStem Technologies to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 24, 2026 • GlobeNewswire Inc. • 03/11/2026 08:05:00 PM
- BioStem Technologies to Present at the 46th Annual TD Cowen Healthcare Conference • GlobeNewswire Inc. • 02/20/2026 12:00:00 PM
- BioStem Technologies Highlights Alignment with FDA’s Openness to Bayesian Statistical Approaches in Clinical Research • GlobeNewswire Inc. • 02/03/2026 09:05:00 PM
- BioStem Technologies Advances Entry into the Acute Wound Care Market with Acquisition of BioTissue Holdings’ Surgical and Wound Care Business • GlobeNewswire Inc. • 01/21/2026 10:30:00 PM
- BioStem Technologies Comments on Withdrawal of CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes • GlobeNewswire Inc. • 01/07/2026 09:05:00 PM
- BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes • GlobeNewswire Inc. • 12/18/2025 12:00:00 PM
- BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference • GlobeNewswire Inc. • 12/10/2025 12:00:00 PM
- BioStem Technologies Expands Product Access in Medicaid • GlobeNewswire Inc. • 11/25/2025 01:59:13 PM
- BioStem Technologies Reports Third Quarter 2025 Financial Results • GlobeNewswire Inc. • 11/13/2025 09:02:00 PM
- BioStem Technologies Announces Filing of Restated Financial Statements • GlobeNewswire Inc. • 11/13/2025 09:01:00 PM
- BioStem Technologies Provides Comments on CMS CY 2026 Final Medicare Reimbursement Rule Changes for Skin Substitutes • GlobeNewswire Inc. • 11/05/2025 09:05:00 PM
- BioStem Technologies Secures Land Purchase at the Research Park at Florida Atlantic University in Boca Raton for Future Headquarters • GlobeNewswire Inc. • 11/05/2025 12:00:00 PM
- BioStem Technologies Reports Positive Top-Line Clinical Results Demonstrating Superior Outcomes with BioRetain® Allograft in Diabetic Foot Ulcers • GlobeNewswire Inc. • 10/31/2025 11:00:00 AM
- BioStem Technologies to Host Third Quarter 2025 Financial Results Conference Call on November 13, 2025 • GlobeNewswire Inc. • 10/30/2025 08:05:00 PM
